LATEST RESEARCH UPDATE
Cytokind's Phase 1 Trial Results Published in Experimental Dermatology. Narrowband ultraviolet B (NB-UVB) phototherapy reduced 28-day mortality by 60%.
We are excited to announce that BARDA is partnering with Cytokind's team to expand its clinical trial to further validate a phototherapy device. Our grant award is the first non-pharmacological therapeutic to be given in an effort to support BARDA's Division of Research, Innovation, and Ventures (DRIVe). The awards announced today are part of BARDA DRIVe's medical countermeasure portfolio.
There awards are part of BARDA DRIVe's medical countermeasure portfolio.
LEADERS IN UVB LIGHT RESEARCH AND ASSOCIATED BLOOD ANALYSIS TO TREAT IMMUNE DISORDERS
FACTS ABOUT UV LIGHT
UV Light & Our Biology
UVB Stabilizes Our Immune System
Sunlight Extends Longevity
Natural Sunlight and UV Treatment in MS
UV Treatment in the Clinic Reduces Relapses by 30% - LEARN MORE
UVB Treatment ≠ to Melanoma